17th – 19th January, 2012, Visiongain Conference Centre, London, UK

Organised By

Advances in bispecific, next-generation and monoclonal antibody development and translation

To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/rabs

Paulo Fontoura, Global Head CNS Translational Medicine, F. Hoffmann-La Roche

Jennifer Sims, Global Head of Biologics Safety & Disposition, Novartis

Ulrich Brinkmann, Scientific Director, Biologics Engineering, Roche Pharma Research and Early Development

Matthew Sleeman, Director of Biology, MedImmune

Lolke de Haan, Director of Toxicology, Biologics Safety Assessment, MedImmune

Andrew Nesbitt, Associate Director, Cimzia Mechanism of Action Group, UCB Celltech

Jürgen Michael Schanzer, Research Scientist Biologics Engineering, Roche Diagnostics

Maria A.T. Groves, Senior Scientist, Lead Generation, ADPE, MedImmune

John McCafferty, Director of Research, University of Cambridge

Kerry Chester, Professor Molecular Medicine, University College London

Christian Rohlff, Chief Executive Officer, Oxford BioTherapeutics

Matthew Baker, Chief Scientific Officer, Antitope

Nicolas Fischer, Head of Research, NovImmune

Lihui Xu, Group Leader, Antibody Technology and Generation, Merrimack Pharmaceuticals

Key Speakers

BOOK NOW!

Driving the Industry Forward | www.futurepharmaus.com

Media Partners

5th Annual Recombinant Antibodies

Pre-conference Workshop, Tuesday 17th January, 2012

Antibody drug conjugates– finally delivering their payload

Led by: Shane Olwill, Senior Director R&D, Pharmacology, Pieris

Conference Introduction5th Annual Recombinant Antibodies

17th - 19th January 2012, London, UK

Dear Colleague, From Kohler and Millstein’s pioneering efforts to today’s multifactorial approach,

monoclonal antibodies have consistently improved the clinical outcome of diseaseprogression.AsshownbyAvastinandLucentis,antibodieshaveblockbusterpotential,nownumbereightoftoday’s20top-sellingbiotechdrugs.Withongoinggrowthratesnearing15%,theglobalmarketwillreach$80by20251asnewapprovalsandagrowingworldpopulationdrivepatientdemand.

Withover25productsapprovedforhumanuseand26candidates inPhase III trials,mAbsremainarguablythemostexcitingproteinstoday.Pharmaceuticalcompanieshavebecomemoreinterested,especiallyinfully-human,bi-specificandscFvproteins,astheseprogressthroughdevelopmentfornewindications includingophthalmic,autoimmuneandviraldiseases.

With competition intensifying, rational design to target multiple disease pathways hasbecomeevermore important in an increasingly crowdedmarket.This includesutilisinginformatics,omics, and systemsbiology insights.Decreasing immunogenicity, improvingreceptor-ligand interactions and decreasing in vivo clearance rates remain ongoingchallenges,asdomoreeffectivebiodistribution,targeting,tissuepenetrationanduptake.

Addressing these needs, Visiongain’s Fifth Annual Recombinant Antibodies conference showcases how such goals are being met by leading experts. Whether your interests lie in basic, pre-clinical, translational or clinical research, business diversification, licensing or partnering, attending this conference will empower you to: •Networkwithkeydecisionmakersat leadingcompanies includingRoche,Novartisand

MedImmune •ImprovethepotencyofIgGmoleculesforADCC,ADCPandCDCapplications •EnhanceimmuneeffectorfunctionsthroughtargetedFcregionengineering •Increaseinvivocirculationtimewithconjugatedimmunoglobulins •Extendpharmacokinetichalf-lifeandexposure •Betterutilise,deployandevaluateinsilicotoolsduringearly-phaseresearch •Optimiseantigen-bindingdomains •Engineerdecreasedimmunogenicity,cross-reactivityandinvivotoxicity •Assessnewtechnologiesforselectingantibodyattributes •Maximisesite-specificdrugloadingforbispecificantibodies •Obtainnewdataoninflammatorydisease,andsolidandliquidcancertargets •Block activation of angiogenic signalling pathways and disrupt the tumour

microenvironment

Ilookforwardtomeetingyouattheconference

Bestregards

Nicholas Stone Head of Conferences

Who should attend?Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents, Professors, Heads, Directors, Principal/Senior Scientists and Managers/Team Leaders of:

• Antibody design, production and development• Recombinant DNA/molecular biotechnology• Protein/biochemical engineering• Biotherapeutics• Assay and cell display technologies• Bio-analytical and protein-analytical R&D, and analytical chemistry • Process development • Preclinical/clinical research and development • Oncology• CNS, autoimmune and inflammatory disease research • Arthritis, colorectal/breast/lymphoma/prostate/lung cancer R&D • Immunobiology and immunogenicity testing• Pharmacovigilance• Business and alliance development • Marketing and licensing• Biosimilars • Contract manufacturing and research organisations • Regulatory affairs, pharmaceutical and patent law• Pharmaceutical and patent law

Media Partners:

PharmiWeb.comistheleadingindustry-sponsoredportalforthepharmaceuticalsector.Supportedbymostoftheleading

pharmaceuticalcorporations,PharmiWeb.comprovidesdynamicreal-timenews,features,eventslistingsandinternationaljobstoindustryprofessionalsacrossEuropeandtheUS.For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGYEUROPEisownedbyBIOTECHNOLOGYWORLD.ItisbasedandlocatedinWarsaw,Poland.BiotechnologyWorldwasfoundedin2007toprovidethe

world’sbiotechandpharmainformationandmarkettomakeituniversallyaccessibleandusefulforscientificandbusinessprocesses.ItsfirststeptofulfillingthatmissionwasbuildingtheBIOTECHNOLOGYEUROPEplatformthatwillallowaquickspreadofinformationindifferentchannels.BIOTECHNOLOGYEUROPEofferscompaniescompletedinternetpublicrelations,publicationandmarketingsolutions.OneofthemainsgoalsofBIOTECHNOLOGYEUROPEistointegratetheBiotechandPharmaSectorinEuropetoglobalbiotechnology,pharmaceuticalandlifescienceactivities.For further information please visit: www.biotechnology-europe.com

FuturePharmaceuticalshasforgedpowerfulrelationshipswithkeyindustryleaderstoprovideaplatformforsuccessfulbrandrecognition,andforseniordecision-makerstohavethemeans

toprocureandplanimplementationstrategiesbasedonthetopicscovered.Positionedtobeanauthoritativeresourcewithintoppharmacompaniesaswellassmall,specialty,andbiotech,FuturePharmaceuticalsmagazineisgearedtocreateadeeppenetrationintoahighlytargetedandresponsiveaudience,bridgingthegapbetweentheindustries’topissuesandthesolutionstop-tiervendorscanprovide.For further information please visit: www.futurepharmaus.com

InPharmistheonlineplatformforexclusivepharmaceuticalnews,comment,contracts,services,jobsandeventsandishometoInPharmjobs.com,PharmafileandPharmafocus.

For further information please visit: www.inpharm.com

Driving the Industry Forward | www.futurepharmaus.com

Sponsorship and exhibition opportunities

Thiseventoffersauniqueopportunitytomeetanddobusinesswithsomeofthekey

playersinthepharmaceuticalandbiotechindustries.Ifyouhaveaserviceorproduct

topromote,youcandosoatthiseventby:

•Hostinganetworkingdrinksreception

•Takinganexhibitionspaceattheconference

•Advertisinginthedelegatedocumentationpack

•Providingbrandedbags,pens,gifts,etc.

Ifyouwouldlikemoreinformationontherangeofsponsorshiporexhibitionpossibilities

forvisiongain's5thAnnualRecombinantAntibodiesConference,pleasecontactus:

Damian Gorman, +44 (0)20 7549 9934

damian.gorman@visiongainglobal.com

Poster PresentationAtabusyconferenceitishardtomakesureeveryonewhosharesyourinterestsknowswhatyouaredoing.MaximiseyourtimeatVisiongain’s5thAnnualRecombinantAntibodiesmeetingbysharingyourresultsinaposterpresentation.Withaplethoraofkeydecisionmakers,takeadvantageofthisseniornetworkingopportunity.

Pleasesendyour200wordabstract,inEnglish,to:info@visiongainglobal.comforapproval.ThedeadlineforsubmissionsisTuesday,10thJanuary,2012.Pleaseincludecontactdetailsforthecorrespondingauthor(s).

Academicinstitutionswillnotbechargedafeeifbookedasfull-pricedelegates.Posterssubmittedbypharmaceuticalandbiotechnologyfirmswillbechargedafeeof£199.

Posterssubmittedbyserviceproviders/vendorsarewelcomeandwillbesubjecttoevaluation.Uponapprovalafeeof£500willapply.Twodelegatesfromyourorganisationmustbebookedatfullpricetopresentaposter.

PleasenotethatallposterswillbedisplayedatthediscretionofVisiongainLtdandaresubjecttoapproval.Duetolimitedspace,pleaseregisteryourinterestearly.

1Visiongain,(2010).TherapeuticMonoclonalAntibodies:WorldMarket2010-2025

Pre-Conference Interactive Workshop5th Annual Recombinant Antibodies

Tuesday 17th January 2012

Antibody drug conjugates– finally delivering their payload

Shane Olwill SeniorDirectorR&D,PharmacologyPieris

Timings: 09:30-10:00 Coffee&Registration10:00- 15:00 Workshop

Timingincludeslunchandrefreshmentbreaks

Led by:

About your workshop leader:

Dr Shane Olwill

Dr Shane Olwill has spent over a decade in oncology-focused drug

discovery, with a specific interest in the development of novel biologics.

At Pieris, Shane is responsible for managing preclinical oncology

programs from discovery into the clinic. He is also responsible for

characterizing ADC applications of anticalins. Prior to joining Pieris,

Shane was Director of Research at Fusion Antibodies Ltd. Shane received

his B.Sc. in Biomedical Sciences and Ph.D. in Molecular Haematology/

Oncology from the University of Ulster.

About: Pieris. The Anticalin Company™

Pieris AG is an independent clinical stage biotechnology company that is

dedicated to the discovery and development of life changing drugs. Our

proprietary technology, the Anticalin® technology, encompasses a novel

class of therapeutic proteins that addresses a broad range of therapeutic

applications and targets. Pieris has a growing, exciting and differentiated

drug pipeline across multiple disease areas. Pieris will commercialize

Anticalin therapeutics through strategic partnerships, involving both

its proprietary pipeline and its de novo drug discovery capabilities. The

company has four ongoing discovery and development collaborations:

Daiichi Sankyo, Takeda San Francisco, Allergan, Sanofi-Aventis and Sanofi-

Pasteur. Pieris is well financed, having closed Series A and B rounds

of venture-backed financing, led by Global Life Science Ventures and

OrbiMed Advisors.

For further information, please visit: www.pieris-ag.com

Agenda:

The development of antibody drug conjugates (ADCs) has faced

considerable hurdles over the past decade with research efforts

hampered by target selection, optimal antibody format, conjugation

chemistries, bioprocessing and choice of drug payloads. However, a new

wave of optimism has emerged following successful clinical trial data

from lead compounds such as TDM-1 (ImmunoGen – Roche/Genentech)

in breast cancer and SGN35 (Seattle Genetics-Millennium/Takeda) being

evaluated for the treatment of Hodgkin’s lymphoma. This has led to a

heightened level of interest in the area.

This workshop will provide an introduction to the development of ADCs

including key selection criteria for ADC components. It will review the

current status of ADCs in development, discussing how they can aid the

delivery of potent anti-neoplastic molecules with reduced toxicity and

improve the therapeutic index when compared to naked antibodies. The

workshop will also introduce how next generation non-IgG scaffolds such

as Anticalins may further enhance their therapeutic index.

About visiongain: Visiongain is a specialist business information company focused on providing cutting edge products and services across the Pharmaceutical/Biotech, Telecommunications, Defence and Finance sectors, which include reports, conferences, online daily news and offline news analysis and bespoke consultancy. With a commitment to innovation and excellence, visiongain offers flexible solutions to meet our clients’ business intelligence needs, providing the right information at the right time to facilitate the commercial decision-making process. Our pharmaceutical products include Pharma Business Daily, the leading daily email newsletter for the pharmaceutical, biotech and healthcare industries, and a range of independent, high-quality, in-depth reports covering focused and topical areas of concern. Our pharmaceutical conferences address the hottest commercial, regulatory and technical topics and provide an ideal forum for debate and networking for pharmaceutical professionals from around the world.

For further information, please visit: www.visiongain.com

09:00 Registration and refreshments

09:30 Opening address from the Chairs

Kerry Chester ProfessorMolecularMedicineUniversity College London

Matthew Sleeman DirectorofBiologyMedImmune

09:40 Biology of Fc receptors: impact on therapeutic antibodies

•FunctionalimportanceofFcγRs

•CD20therapeuticantibodiesdependonimmunecellFcreceptorinteractions

•TumourburdendeterminestheeffectormechanismofCD20antibodies

Jeanette Leusen AssociateProfessorUniversity Medical Centre Utrecht

10:20 Antibody engineering by design

•PKandreceptoroccupancymodelstofuture-proofantibodydesign

•Harnessingthepowerofphagedisplaytomeetspecificdesigncriteria

•Combiningbiology,pharmacologyandPDtotranslatepreclinicalobservationsintotheclinic

•PhaseIclinicalresultsandtheirrelationtothetheoreticalmodel

Matthew Sleeman DirectorofBiologyMedImmune

11:00 Morning refreshments

11:20 Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains

•Constructionofanoveltetravalent,bispecificantibodytoblockHIVentry

•DesignoptimisationofscFvsincludingdisulfideandincreasedlinkerlengthstabilization

•EnhancedantiviralpotencyagainstwildtypeandCCR5-antibodyresistantHIV-1strains

Jürgen Michael Schanzer ResearchScientistBiologicsEngineeringRoche Diagnostics

12:00 �κλ�-body: a manufacturing friendly bispecific antibody format

•Incontrasttootherbispecificformats,κλ-BodiesareunmodifiedfullyhumanIgGs

•κλ�-Bodiesrelyontheassemblyofakappaandalambdalightchainwithacommonheavychain

•Developmentofastreamlinedplatformforproducing�κλ�-bodies

Nicolas Fischer HeadofResearchNovImmune

12:40 Networking lunch

13:40 Bispecific antibodies for targeted payload delivery

•Generation&optimisationofhapten-bindingbispecificantibodies

•Complexationandtargeteddeliveryofhaptenylatedpayloads

•Targetedpayloaddeliveryinvitroandinvivo

Ulrich Brinkmann ScientificDirector,BiologicsEngineeringRoche Pharma Research and Early Development

14:20 Rational engineering of antibody therapeutics targeting multiple oncogene pathways

•Molecularformatandpharmaceuticalpropertiesinbispecificantibodydesign

•Identifyingbesttargetsandoptimaldesigncharacteristics

•Engineeringabispecificantibodythroughatherapeuticdesigncycle

Lihui Xu GroupLeader,AntibodyTechnologyandGenerationMerrimack Pharmaceuticals

15:00 Afternoon refreshments

15:20 PASylation: a superior approach to engineer antibody fragments with extended plasma half-life

•Fcfusion,HSAfusionandPEGylationstrategiestoachieveprolongedcirculation

•PASylation(geneticfusionwithalongdisorderedpolypeptidecomprisingPro,AlaandSerresidues)asanalternative

•PreclinicalapplicationsofPASylationforFabfragmentsandotherbiopharmaceuticals

Arne Skerra ManagingDirectorXL-protein

16:00 Monoclonal and next-generation antibodies- where are we and what are the prospects for the future?

Topicsdiscussedwillincludeimprovingantibodyefficacyfrominitialtargetbinding,anddualblockadeofdiseasemediatorswithbispecificantibodies.Thefutureofconjugatedtherapies,engineeringenhancedPK/PDandtheimpactofsystemsbiologyonclinicaldevelopmentwillalsobediscussed.Jointhislivelysessionandemailyourquestionsforthepanelto:nicholas.stone@visiongainglobal.com

16:40 Closing remarks from the Chair

16:50 Networking drinks

Take your discussions further and build new relationships in a relaxed and informal setting

Day 15th Annual Recombinant Antibodies

Wednesday 18th January 2012

Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

PAN

EL D

ISC

USS

ION

Day 25th Annual Recombinant Antibodies

Thursday 19th January 2012

09:00 Registration and refreshments

09:30 Opening address from the Chair

Paulo Fontoura GlobalHeadCNSTranslationalMedicineF. Hoffmann-La Roche

09:40 Beyond natural antibodies: the power of in vitro display technologies

•Uniquefeaturesofdisplaytechnologies

•Recognitionofmodificationsinproteins,andcellsurfacereceptors

•ExploitingtherecombinantnatureofinvitroselectedmAbs

John McCafferty DirectorofResearchUniversity of Cambridge

10:20 Generation of differentiated biological therapeutics

•AreviewofbiologicsdiscoveryatMedImmune

•Projectcasestudyexampleswillbegiven

•Examplesofdifferentiatedproductswillbeincluded

Maria Groves SeniorScientist,LeadGeneration,ADPEMedImmune

11:00 Morning refreshments

11:20 On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models

•Contributionsofinvitroandinvivostudies

•Rolesandlimitationsofinvivoanimalmodels

•Overcomingchallengesforclinicalpharmacology

Jennifer Sims GlobalHeadofBiologicsSafety&DispositionNovartis

12:00 Modulation of Fc receptor function: from principle to translation in the clinic

•Fcengineeringresultingindecreasedorincreasedeffectorfunction,orhalflifeextension

•UtilityoftranslationalPK/PDtopredicthumansafetyandefficacy

•Threeexamplesillustratingissuesarisingduringdrugdevelopment

Lolke de Haan DirectorofToxicology,BiologicsSafetyAssessmentMedImmune

12:40 Networking lunch

13:40 Presentation to be announced

Andrew Nesbitt AssociateDirector,CimziaMechanismofActionGroupUCB Celltech

14:20 Monoclonal antibody therapy in multiple sclerosis: paradigm shifts and emerging challenges

•mAbsmayofferconsiderableadvantagesoverothertherapiesforMS

•However,efficacycomeswithsignificantclinicalrisks

•Obtainingthebestbenefit-riskratio,monitoringandpreventingemergentsafetyconcerns

15:00 Afternoon refreshments

15:20 Generation of therapeutic antibodies against inflammatory disease and cancer targets, with a low risk of clinical immunogenicity

Matthew Baker ChiefScientificOfficerAntitope

16:00 Conjugated mAbs for cancer treatment

•Improvedcytotoxictreatments

•Anti-tumouractivitythroughtargetcellactivation

•Evidencefrominvivotrials

Christian Rohlff ChiefExecutiveOfficerOxford BioTherapeutics

16:40 Chair’s closing remarks

16:50 End of conference

CA

SE S

TUD

YC

ASE

STU

DY

How to bookEmail:piyush.patel@visiongain.comWeb:http://www.visiongain.com/rabs

UK Office:Tel: +44(0)207549 9961Fax:+44(0)2075499932 VisiongainLtdBSGHouse230CityRoadLondonEC1V2QYUK

General informationVenue:Venue:Directions:VisiongainConferenceCentre230CityRoad,London,EC1V2TT.UnitedKingdom.ClosesttubestationisOldStreet(NorthernLine).Accommodation:ThistleCityBarbican,CentralStreet,Clerkenwell,London,EC1V8DS,Phone:08713769004/+448453058304,Fax:08713769104/+448453058343http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.htmlTravelodgeLondonCityRoadHotel,7-12CityRoad,London,EC1Y1AE,Tel:08719846333,Fax:02076282503,http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340

Payment terms:Visiongainrequirethefullamounttobepaidbeforetheconference.VisiongainLtdmayrefuseentrytodelegateswhohavenotpaidtheirinvoiceinfull.Acreditcardguaranteemayberequestedifpaymenthasnotbeenreceivedinfullbeforetheevent.VisiongainLtdreservestherighttochargeinterestonunpaidinvoices.

Substitutions/name changes or cancellations: Thereisa50%liabilityonallbookingsoncemade,whetherbypost,fax,emailorweb.Thereisanorefundpolicyforcancellationsreceivedonorafteronemonthbeforethestartoftheevent.Shouldyoudecidetocancelafterthisdate,thefullinvoicemustbepaid.Conferencenoteswillthenbesenttoyou.Unfortunately,weareunabletotransferplacesbetweenconferences.However,ifyoucannotattendtheconference,youmaymakeasubstitution/namechangeatanytime,aslongasweareinformedinwritingbyemail,faxorpost.Namechangesandsubstitutions must be from the same company or organisation and are not transferable betweencountries.Pleasenotethatdiscounteddelegatesplacesatavisiongaineventarenonrefundable.

Invoice alterations:Therewillbeanadministrationchargeof£50foranychangestoaninvoice,excluding substitutions/name changes, requested by the customer. This will be charged to thecustomerbycreditcardpriortothechangesbeingmade.

Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executivebriefingcontent,timing,speakersorvenuewithoutnotice.TheeventmaybepostponedorcancelledduetounforeseeneventsbeyondthecontrolofvisiongainLtd.Ifsuchasituationarises,wewilltrytorescheduletheevent.However,visiongainLtdcannotbeheldresponsibleforanycost,damageorexpenses,whichmaybeincurredbythecustomerasaconsequenceoftheeventbeingpostponedorcancelled.Wethereforestronglyadviseallourconferenceclientstotakeoutinsurancetocoverthecostoftheregistration,travelandexpenses.

Data Protection: Visiongain Ltd gathers and manages data in accordance with the DataProtectionAct1988.YourpersonalinformationcontainedinthisformmaybeusedtoupdateyouonvisiongainLtdproductsandservicesviapost,telephone,faxoremail,unlessyoustateotherwise.Wemayalsoshareyourdatawithexternalcompaniesofferingcomplementaryproductsorservices.Ifyouwishforyourdetailstobeamended,suppressedornotpassedontoanyexternalthirdparty,pleasesendyourrequesttotheDatabaseManager,visiongainLtd,BSGHouse,226-236CityRoad,London,EC1V2QY.Alternatively,youcanvisitourwebsiteatwww.visiongain.comandamendyourdetails.Pleaseallowapproximately30daysforyourremovalorupdaterequesttobeappliedtoourdatabase.Followingyourremovalorupdaterequest,youmayreceiveadditionalpiecesofcommunicationfromvisiongainLtdduringthetransitionalperiod,whilstthechangesarecomingintoeffect.

Fee: Theconferencefeeincludeslunch,refreshmentsandconferencepapersprovidedontheday.This feedoesnot include travel, hotel accommodation, transfersor insurance, (whichwe stronglyrecommendyouobtain).

VAT: VATwillbechargedatthelocalrateoneachconference.DelegatesmaybeabletorecoverVATincurredbycontactingEurocashCorporationplc+44(0)1273325000,eurocash@eurocashvat.com.Eurocashspecialiseinrecoveringcross-borderVAT.

How we will contact you: VisiongainLtd’spreferredmethodofcommunicationisbyemailandphone.Pleaseensurethatyoucompletetheregistrationforminfullsothatwecancontactyou.

Unable to attendObviouslynothingcomparestobeingtherebutyouneednotmissout.Simplyticktheboxandsendwithyourpayment.YouwillreceivespeakertalksinPDFstwoweeksaftertheevent.

Yes, please send me speaker talks Price£550 VAT:£110 Total:£660

Conf.codePP

Standard PricesConference and workshop Fee: £1699 VAT: £339.80 Total: £2038.80

Conference only Fee: £1299 VAT: £259.80 Total: £1558.80

Workshop only Fee: £599 VAT: £119.80 Total: £718.80

Number of bookings: Total cost:

Promotional Literature DistributionDistribution of your company’s promotional literature to all conference attendees

Fee: £999 VAT: £199.80 Total: £1198.80

Details

Forename: Surname:

JobTitle: Company:

MainSwitchboardNumber:

Address:

Country: Postcode:

Phone: Fax:

Email:

Signature:

IconfirmthatIhavereadandagreetothetermsandconditionsofbooking

Methods of paymentPaymentmustbemadeinsterling

By Mail: Completeandreturnyoursignedregistrationformtogetherwithyourchequepayable

toVisiongainLtdandsendto:visiongainLtd,BSGHouse,226-236CityRoad,London,EC1V2QY,UK

By Fax: Completeandfaxyoursignedregistrationformwithyourcreditcarddetails

to+44(0)2075499932

By Phone:Calluson+44(0)2073366100withyourcreditcarddetails

By Credit Card:Fillinyourcarddetailsbelowandfaxbackto+44(0)2075499932

By Bank Transfer:

VisiongainLtd A/C:visiongainLtd

BarclaysBank SortCode:20-71-64

PiccadillyBranch AccountNo:60387118

48RegentStreet SwiftCode:BARCGB22

London,W1B5RA IBAN:GB80BARC20716460387118

Please debit my credit card:

Access MasterCard Visa AmericanExpress

Cardnumber:

ExpiryDate:

Securitynumber(last3digitsonbackofcreditcard):

Signature:

Cardholder’sname:

News updatesPleasetickifyoudonotwanttoreceiveemailnewsupdatesinthefuture

Registration Form5th Annual Recombinant Antibodies

17th - 19th January 2012, London, UK

www.visiongain.com/rabs

5th Annual Recombinant Antibodies 17th - 19th January 2012Location:VisiongainConferenceCentre

Address:230CityRoadLondonEC1V2TTUK

City Road

Old Street

City Road

Pentonville Road

Old Street

Angel